Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (PLRX)
NASDAQ:PLRX
RESEARCH TOOLSreports
PLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.43 - $16.81
Previous CloseN/A
Volume34.91K
Average Volume (3M)2.80M
Market Cap
$209.34M
Enterprise Value$336.49M
Total Cash (Recent Filing)$22.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 04, 2025EPS Estimate
-0.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.34
Shares Outstanding60,853,622
10 Day Avg. Volume2,542,958
30 Day Avg. Volume2,799,191
Standard Deviation0.26
R-Squared0.04
Alpha-0.00877
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)132.49
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit212.97
Enterprise Value/Ebitda-1.71
Forecast
1Y Price Target
$6.00Price Target Upside74.42% Upside
Rating ConsensusHold
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Expert PanelPLRX announced it is assembling an outside expert panel to review unblinded trial data, which indicates proactive steps towards resolving the trial issues.
Regulatory OutlookThe FDA was informed but has not issued a clinical hold, which is a positive.
Bears Say
Trial UncertaintyPLRX has limited visibility on the rationale for the DSMB's pause recommendation.
---
Ownership Overview
4.40% Insiders
19.84% Mutual Funds
0.50% Other Institutional Investors
63.51% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PLRX FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $2.43 and its highest was $16.81 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is $209.34M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is today.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$0.969 by $0.019.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.98.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 60,853,622 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -$0.95 in its last earnings report, beating expectations of -$0.969. Following the earnings report the stock price went down -1.251%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in PLRX
---
Pliant Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.00 (74.42% Upside)
$6.00 (74.42% Upside)
Blogger Sentiment
Bullish
PLRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 45.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.30%
12-Months-Change
Fundamentals
Return on Equity
-47.52%
Trailing 12-Months
Asset Growth
-17.54%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
---
PLRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(74.42% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Nektar Therapeutics
―
Vertex Pharmaceuticals
―
Blueprint Medicines
―
Galapagos
―
Best Analysts Covering PLRX
1 Year
1 Year Success Rate
8/25 ratings generated profit
1 Year Average Return
-1.95%
reiterated a buy rating 19 days ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 32.00% of your transactions generating a profit, with an average return of -1.95% per trade.
---